Ekso Bionics Unveils Presentation on Enhancing Human Function with Advanced Robotics
Ekso Bionics Holdings Inc. has unveiled an investor presentation showcasing its advancements in health and quality of life through robotics, particularly in neuro-rehabilitation. The company has deployed over 1,000 exoskeleton devices across 500 centers globally. Plans include a limited research release in 2024 and a commercial launch of the NOMAD product in 2025. The acquisition of Indego and a CMS reimbursement strategy of $91,000 are also highlighted as part of their market expansion efforts.
Ekso Bionics Holdings Inc. has released an investor presentation detailing its advancements in the field of health and quality of life through advanced robotics. The company highlights its focus on neuro-rehabilitation, with Ekso exoskeletons being used in inpatient rehabilitation hospitals, outpatient rehab facilities, and VA medical centers. As of now, over 500 centers and 1,000 devices have been deployed worldwide. In the future, Ekso Bionics plans to expand its market reach, with a limited release for research in 2024 and a commercial release expected in 2025 for its new product, NOMAD. The presentation also notes Ekso Bionics’ acquisition of Indego from Parker Hannifin and mentions a CMS reimbursement of $91,000 as part of its strategy to advance a scalable go-to-market approach for personal exoskeletons. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ekso Bionics Holdings Inc. published the original content used to generate this news brief on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
